Category: Parkinson's Disease: Cognitive functions
Objective: To validate NIMHANS Neuropsychological Battery for Elderly( NNB-E) and evaluate cognitive impairment in Parkinson’s disease (PD) patients in comparison with healthy controls.
Background: Cognitive impairment is a common nonmotor feature of PD. Diagnosis of mild cognitive impairment is challenging and routinely missed in clinical practice. Our study aimed to study the efficacy of NNB-E in diagnosing the subtle cognitive deficits in PD patients.
Method: We recruited 31 PD patients and 31 healthy controls in the current study. We validated NNB-E using ROC curve analysis, Cronbach’s alpha, principal component analysis, Pearson product-moment correlation and studied the cognitive impairments using NNB-E in the non-demented PD patients and controls who scored ≥ 24 on Hindi Mental Status examination (HMSE) score
Results: Cognitive performance of PD patients was poor compared to controls. NNB-E showed good internal consistency and construct validity with Crohnbachs alpha of 0.861 and AUC of 0.878. The battery was able to detect mild cognitive impairment in 74.1 % patients and 6.4 % controls. ROC curve showed an overall sensitivity of the battery was 73.2% and specificity was 92.6 % at optimal cutoff score. Different cut off values set for defining PD-MCI as per MDS task force criteria resulted in varying frequencies of MCI ranging from 25.8% to 71%.
Conclusion: Our study established the validity of NNB-E in PD patients and this tool was suitable for diagnosing PD-MCI and discriminating patients from normal controls in Indian population. This study also showed PD MCI at various cutoff scores with greater impairment in executive and attention domains.
References: 1. Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D et al.. Cognitive decline in Parkinson disease. Nat Rev Neurol 2017; 13:217–231.
2. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: The Norwegian ParkWest study. JAMA Neurol 2013; 70:580–586.
3. Muslimović D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005; 65:1239–1245.
4. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012; 27:349–356.
5. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 2010; 25:2649–53.
6. Tripathi R, Kumar JK, Bharath S, Marimuthu P, Varghese M. Clinical validity of NIMHANS neuropsychological battery for elderly: A preliminary report. Indian J Psychiatry 2013; 55:279–282.
To cite this abstract in AMA style:
R. Yadav, R. Botta, K. Kumar, BM. Kutty, A. Mahadevan, PK. Pal. NIMHANS Neuropsychological Battery for Elderly in Parkinson’s disease patients: Validation and diagnosis using MDS PD-MCI task force criteria in Indian population [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/nimhans-neuropsychological-battery-for-elderly-in-parkinsons-disease-patients-validation-and-diagnosis-using-mds-pd-mci-task-force-criteria-in-indian-population/. Accessed November 23, 2024.« Back to 2022 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/nimhans-neuropsychological-battery-for-elderly-in-parkinsons-disease-patients-validation-and-diagnosis-using-mds-pd-mci-task-force-criteria-in-indian-population/